Emerging therapies in rosacea

J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S57-65. doi: 10.1016/j.jaad.2013.04.041.

Abstract

Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.

Keywords: SDD; carvedilol; ivermectin; medical therapy; permethrin; rosacea; subantimicrobial dose doxycycline; subantimicrobial-dose doxycycline.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents
  • Antiparasitic Agents / therapeutic use
  • Cytokines / therapeutic use
  • Doxycycline / therapeutic use
  • Erythema / drug therapy
  • Humans
  • Ivermectin / therapeutic use
  • Mite Infestations / drug therapy
  • Permethrin / therapeutic use
  • Rosacea / drug therapy*
  • Rosacea / parasitology
  • Rosacea / physiopathology

Substances

  • Anti-Bacterial Agents
  • Antiparasitic Agents
  • Cytokines
  • Permethrin
  • Ivermectin
  • Doxycycline